Promising New Target for
|Tumors are characterized by extensive inflammatory infiltrates, which can comprise up to 25 percent of the tumor's mass. Myeloid cells invade tumors in response to diverse inflammatory stimuli produced by the tumor. Invading myeloid cells differentiate into a type of macrophage that promotes tumor angiogenesis, growth and metastasis and inhibits anti-tumor immunity. In the June 14 issue of Cancer Cell, Schmid et al. demonstrate that tumor inflammation (myeloid cell invasion of tumors) requires PI3kinase gamma, a gatekeeper enzyme that is primarily expressed by myeloid cells. Inhibitors of PI3kinase gamma strongly inhibit tumor inflammation, growth and metastasis for a wide variety of cancers. PI3kinase gamma inhibitors hold promise as a new class of general cancer therapeutic agents.|
“Most strategies targeting the role of myeloid cells in cancer have focused on reducing their expression of inflammatory molecules,” Varner explained. “We’ve found a single convergent point – the PI-3 kinase-gamma enzyme – that, when blocked, appears to result in significant suppression of tumor inflammation and growth regardless of the initiating event. It could be a very important therapeutic target for future cancer treatments and could impact most, if not all, types of solid cancer.”
Michael Karin, PhD, distinguished professor of pharmacology in UCSD’s Laboratory of Gene Regulation and Signal Transduction and a pioneer in inflammation research, agreed: “I think that the inhibition of PI-3K activity represents a very interesting and promising approach for inhibition of tumor-associated inflammation. It seems to fully normalize the tumor microenvironment and provide a new addition to our armamentum of anti-cancer drugs.”
Varner said a number of biotechnology companies are pursuing potential drugs using PI-3-kinase inhibitors to treat diseases from cancer to heart disease to arthritis. The PI-3-kinase-gamma protein may be a particularly promising therapeutic target, because it is not widely expressed in the body, and its inhibition would likely produce fewer side effects than many therapeutics.
Co-authors of the research are Michael C. Schmid, Christie J. Avraamides, Philippe Foubert, Joan R.E. Manglicmot, Xiaodan Song and Wolfgang Wrasidlo of the UCSD Moores Cancer Center; Holly C. Dippold and Mark H. Ginsberg, UCSD Department of Medicine; Irene Franco and Emilio Hirsch, Department of Genetics, Biology and Biochemistry, Molecular Biotechnology Center, School of Medicine, University of Torino, Italy; Lesley G. Ellies, UCSD Department of Pathology; Sara L. Blair, UCSD Department of Surgery; and Lissette M. Acevedo and David A. Cheresh, UCSD Moores Cancer Center and UCSD Department of Pathology.
Funding for this research came, in part, from grants from the National Institutes of Health and the California Tobacco Related Disease Research Program.
Media Contacts: Scott LaFee, 619-543-6163, or email@example.com